发明名称 |
PERSONALIZED TREATMENT OF CANCER USING FGFR INHIBITORS |
摘要 |
The present invention relates to a method for predicting the responsiveness of cancer cells to FGFR1 inhibitors, which comprises the evaluation of the status of FGFR1 gene and the status of MYC. A kit useful for carrying out the method is also provided. In addition, a method of treating cancer such as lung cancer is also provided which includes determining the status of FGFR1 gene and the status of MYC gene, and administering to the cancer patient an FGFR1 inhibitor if the tumor tissue or cells exhibit an increased expression or amplification of the FGFR1 gene, as well as an increased expression or amplification of the MYC gene. |
申请公布号 |
US2015335643(A1) |
申请公布日期 |
2015.11.26 |
申请号 |
US201514716883 |
申请日期 |
2015.05.20 |
申请人 |
Thomas Roman K.;Malcher Florian |
发明人 |
Thomas Roman K.;Malcher Florian |
分类号 |
A61K31/506;C12Q1/68 |
主分类号 |
A61K31/506 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating cancer comprising administering an effective amount of an FGFR1 inhibitor to a cancer patient, wherein tumor cells or tissue obtained from the patient has been detected to exhibit (1) focal FGFR1 gene amplification or FGFR1 gene overexpression, and (2) MYC gene amplification or MYC gene overexpression. |
地址 |
Cologne DE |